ATE230600T1 - Verwendung eines thienotriazoldiazepins zur erhöhung des apolopoproteins a-i niveaus - Google Patents

Verwendung eines thienotriazoldiazepins zur erhöhung des apolopoproteins a-i niveaus

Info

Publication number
ATE230600T1
ATE230600T1 AT96930137T AT96930137T ATE230600T1 AT E230600 T1 ATE230600 T1 AT E230600T1 AT 96930137 T AT96930137 T AT 96930137T AT 96930137 T AT96930137 T AT 96930137T AT E230600 T1 ATE230600 T1 AT E230600T1
Authority
AT
Austria
Prior art keywords
pct
levels
thienotriazolediazepine
apolopoprotein
increase
Prior art date
Application number
AT96930137T
Other languages
English (en)
Inventor
Herman Kempen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE230600T1 publication Critical patent/ATE230600T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT96930137T 1995-09-09 1996-08-30 Verwendung eines thienotriazoldiazepins zur erhöhung des apolopoproteins a-i niveaus ATE230600T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95114163 1995-09-09
PCT/EP1996/003814 WO1997009048A1 (en) 1995-09-09 1996-08-30 Use of a thienotriazolodiazepine to increase apolipoprotein a-i levels

Publications (1)

Publication Number Publication Date
ATE230600T1 true ATE230600T1 (de) 2003-01-15

Family

ID=8219597

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96930137T ATE230600T1 (de) 1995-09-09 1996-08-30 Verwendung eines thienotriazoldiazepins zur erhöhung des apolopoproteins a-i niveaus

Country Status (14)

Country Link
US (1) US5854238A (de)
EP (1) EP0853480B1 (de)
JP (1) JPH11512107A (de)
KR (1) KR19990044460A (de)
CN (1) CN1101680C (de)
AT (1) ATE230600T1 (de)
AU (1) AU725249B2 (de)
BR (1) BR9610390A (de)
CA (1) CA2230477A1 (de)
DE (1) DE69625696T2 (de)
DK (1) DK0853480T3 (de)
ES (1) ES2188783T3 (de)
TR (1) TR199800406T1 (de)
WO (1) WO1997009048A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6253569B1 (en) * 1999-05-07 2001-07-03 James J. Hall Portable storage unit for game animals
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
EP1426046A4 (de) 2001-09-14 2005-11-02 Shionogi & Co Neuartige verwendung einer tricyclischen verbindung
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
US6930085B2 (en) 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
EP1827472A4 (de) 2004-12-06 2012-09-05 Univ California Verfahren zur verbesserung der struktur und funktion von arteriolen
EP2682400B1 (de) 2007-08-28 2017-09-20 Uab Research Foundation Synthetische Apolipoprotein E nachahmende Polypeptide und Anwendungsverfahren
AU2008296487A1 (en) 2007-08-28 2009-03-12 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
AU2009309691B2 (en) * 2008-10-30 2015-04-02 Circomed Llc Thienotriazolodiazepine derivatives active on apo A
WO2011143651A1 (en) * 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating metabolism
EP2902030B1 (de) 2010-05-14 2016-09-14 Dana-Farber Cancer Institute, Inc. Thienotriazolodiazepine Verbindungen zur Behandlung von Neoplasie
CA2799381A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Male contraceptive compositions and methods of use
BR112012029057A2 (pt) 2010-05-14 2020-10-13 Dana-Farber Cancer Institute, Inc. composições e métodos de tratamento de leucemia
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
US11446309B2 (en) 2013-11-08 2022-09-20 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
RU2016134947A (ru) 2014-01-31 2018-03-01 Дана-Фарбер Кансер Институт, Инк. Производные диаминопиримидин бензолсульфона и их применение
JP2017504651A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体の使用
WO2015131113A1 (en) 2014-02-28 2015-09-03 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
AU2015298263B2 (en) 2014-07-31 2020-05-14 Anji Pharmaceuticals, Inc. ApoE mimetic peptides and higher potency to clear plasma cholesterol
JP2017525759A (ja) 2014-08-08 2017-09-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジヒドロプテリジノン誘導体およびその使用
JP2017526741A (ja) 2014-08-08 2017-09-14 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体およびその使用
WO2016069578A1 (en) 2014-10-27 2016-05-06 Tensha Therapeutics, Inc. Bromodomain inhibitors
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
RU2750164C2 (ru) 2015-09-11 2021-06-22 Дана-Фарбер Кэнсер Инститьют, Инк. Цианотиенотриазолодиазепины и пути их применения
BR112018004617A2 (pt) 2015-09-11 2018-09-25 Dana Farber Cancer Inst Inc acetamida tienotriazoldiazepinas e usos das mesmas
CR20180336A (es) 2015-11-25 2018-08-06 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
MX2020013608A (es) 2018-06-13 2021-03-09 Worg Pharmaceuticals Hangzhou Co Ltd Preparacion de derivados de triazepina condensados y su uso como inhibidores de bet.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4155913A (en) * 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
PH12303A (en) * 1973-02-08 1979-01-16 Hoffmann La Roche Thienotriazolodiazepine derivatives
JPS50100096A (de) * 1974-01-08 1975-08-08

Also Published As

Publication number Publication date
JPH11512107A (ja) 1999-10-19
AU725249B2 (en) 2000-10-12
EP0853480A1 (de) 1998-07-22
US5854238A (en) 1998-12-29
EP0853480B1 (de) 2003-01-08
DE69625696D1 (de) 2003-02-13
DE69625696T2 (de) 2003-10-16
BR9610390A (pt) 1999-07-06
AU6930396A (en) 1997-03-27
CN1101680C (zh) 2003-02-19
CA2230477A1 (en) 1997-03-13
MX9801753A (es) 1998-08-30
CN1195989A (zh) 1998-10-14
KR19990044460A (ko) 1999-06-25
TR199800406T1 (en) 1998-05-21
DK0853480T3 (da) 2003-05-05
ES2188783T3 (es) 2003-07-01
WO1997009048A1 (en) 1997-03-13

Similar Documents

Publication Publication Date Title
ATE230600T1 (de) Verwendung eines thienotriazoldiazepins zur erhöhung des apolopoproteins a-i niveaus
TR199901276T2 (xx) Farnezil protein transferaz inhibisyonu i�in yararl� bile�ikler.
ES2142593T3 (es) Poliuretanos altamente funcionalizados.
DE69528470D1 (de) Thienopyridin und thienopyrimidinderivate und ihre verwendung als entzündungshemmende mittel
BR9813508A (pt) Inibição de replicação viral associada com membrana
DK0865498T3 (da) Fremgangsmåde til fremstilling af substituerede arylmælkesyreholdige cyclodepsipeptider med 24 ringatomer
AU4623396A (en) 1-aryl-2-acylamino-ethane compounds and their use as neurokinin especially neurokinin 1 antagonists
AU4080097A (en) Piperazino derivatives as neurokinin antagonists
DE69629023D1 (de) Piperazino-derivative als neurokininantagonisten
IL122606A (en) (S)-hydroxa-nitrile-lyase
DE69636393D1 (de) Montirelin zur verhinderung der schlafapnoe
AU6378994A (en) Plant promoter, microorganisms and plant cells containing a unit for the expression of a protein of interest comprising said promoter
GR3035237T3 (en) Algicide combination
DE69623767D1 (de) Verwendung von pyrrolidinderivaten zur behandlung des alkoholismus
DE69613685D1 (de) D-aminosäure-oxidase kodierendes dns-fragment
DE69619530D1 (de) Zyklische somatostatinanaloge mit wachstumhormon inhibierender aktivität
DE69213660D1 (de) Verwendung von 1-(beta-d-arabinofuranosyl)-5-propynyluracil zur senkung des serumcholesterins
DE69930419D1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
DE69814401D1 (de) 2,3-benzodiazepin-derivate
ZA961044B (en) New pyridine and pyridazine derivatives, processes for the production thereof and pharmaceutical agents containing these compounds.
AU2003261230A1 (en) Apolipoprotein e stable folding intermediate and methods of use thereof
WO2001079539A3 (de) Verfahren zur anwendung von transfiziebaren konstruktionen aus luziferase und dem promotor des menschlichen period1-gens zur identifizierung neuer wirkstoffe die den tag/nacht-rhythmus und den schlaf beeinflussen
PT971714E (pt) Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia
TR199901273T2 (xx) Farnezil protein transferaz inhibisyonu i�in yararl� bile�ikler.
AU6661394A (en) Purification of fluoronucleosides

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0853480

Country of ref document: EP

REN Ceased due to non-payment of the annual fee